ArticleJournal of hematology & oncology2017

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.

Narendranath Epperla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.